^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD163 expression

    i
    Other names: CD163, CD163 Molecule, M130, Scavenger Receptor Cysteine-Rich Type 1 Protein M130, Hemoglobin Scavenger Receptor, CD163 Antigen, SCARI1, MM130, Macrophage-Associated Antigen
    Entrez ID:
    9332
    Related biomarkers:
    Expression
    Others
    11h
    Fibrinogen-Like Protein 2 Protects the Aggravation of Hypertriglyceridemia on the Severity of Hypertriglyceridemia Acute Pancreatitis by Regulating Macrophages. (PubMed, Shock)
    FGL2 knockout in HTG and HTG-AP mice resulted in increased inflammatory responses and a significant imbalance in M2 macrophages. These findings suggest that FGL2 plays a crucial role in mitigating the aggravation of HTG on the severity of HTG-AP by modulating macrophage activity.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • IL1B (Interleukin 1, beta)
    |
    CD163 expression
    9d
    CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov)
    P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
    |
    KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    19d
    HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression. (PubMed, Diagn Pathol)
    In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.
    Journal
    |
    CD163 (CD163 Molecule) • HOXA9 (Homeobox A9)
    |
    CD163 expression
    21d
    The Role of Soluble CD163 (sCD163) in Human Physiology and Pathophysiology. (PubMed, Cells)
    The sCD163 levels have been correlated with the severity, stage of the disease, and clinical outcome for many of these conditions. This review article summarizes the expression and role of sCD163 and its precursor protein, CD163, outlines the sCD163 generation mechanisms, the biological activities, and the known underlying molecular mechanisms, with an emphasis on its impact on the endothelium and its contribution in the pathophysiology of human diseases.
    Review • Journal
    |
    CD163 (CD163 Molecule)
    |
    CD163 expression
    24d
    Oral squamous cell carcinomas drive monocytes into immunosuppressive CD25+CD163+CD206+ macrophages. (PubMed, Oral Oncol)
    CD25 enhanced expression was confirmed on H143-CM moMΦ. Collectively, these data indicate that the CM from OSCC cell lines promotes the differentiation of functionally immunosuppressive macrophages resembling TAMs, and contributes to the understanding of how OSCCs create an immunosuppressive cellular environment that favors tumor growth.
    Journal
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • ITGAX (Integrin Subunit Alpha X) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CD163 expression • MRC1 expression
    25d
    The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms. (PubMed, Sci Rep)
    The immunological landscape of Pan-NEN offers potential prognostic value and therapeutic targets. The findings suggest that immunotherapy, particularly targeting the PD-1/PD-L1 pathway, may serve as a promising strategy for the treatment of Pan-NEN, especially for Pan-NEC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • PD-L1 underexpression • PD-1 expression • CD163 expression • FOXP3 expression
    29d
    Effect of Galantamine on Inflammation and Cognition (clinicaltrials.gov)
    P2, N=63, Completed, University of Pennsylvania | N=114 --> 63
    Enrollment change
    |
    CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD14 (CD14 Molecule) • NDUFA2 (NADH:Ubiquinone Oxidoreductase Subunit A2)
    |
    CD8 expression • CD163 expression
    1m
    Integrative analysis of H&E and IHC identifies prognostic immune subtypes in HPV related oropharyngeal cancer. (PubMed, Commun Med (Lond))
    Integrating H&E and IHC data enhances the functional characterization of immune phenotypes of the TME with biological interpretability, and improves patient stratification in HPV( + ) OPSCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    CD8 expression • CD8-H • CD163 expression • CD163 underexpression
    2ms
    Vitamin D3 reduces the expression of M1 and M2 macrophage markers in breast cancer patients. (PubMed, Sci Rep)
    The decrease in both M1 and M2 macrophage markers by calcitriol or their negative correlation with CYP27B1 indicate the modulatory, but rather anticancer activity of VD. The intensity of these effects was the strongest in postmenopausal patients and those without metastases.
    Journal
    |
    CD163 (CD163 Molecule) • CD44 (CD44 Molecule) • CD200R1 (CD200 Receptor 1) • CD80 (CD80 Molecule) • MSR1 (Macrophage Scavenger Receptor 1)
    |
    CD20 expression • CD44 expression • CD163 expression • CD200 expression
    2ms
    Comparative immunohistochemical expression of Beta catenin and CD163 between dysplastic / non-dysplastic oral lichen planus and lichenoid lesions (EX-VIVO STUDY). (PubMed, BMC Oral Health)
    Evidence of the relationship between beta catenin and M2 macrophages (+ CD163) may enhance the development of macrophage-based strategies for treatment and improve the prognosis of such cases.
    Preclinical • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD163 (CD163 Molecule)
    |
    CD163 expression • CTNNB1 expression
    2ms
    Analysis of macrophage polarization and regulation characteristics in ovarian tissues of polycystic ovary syndrome. (PubMed, Front Med (Lausanne))
    This study elucidated the polarization status and regulatory characteristics of macrophages in ovarian tissues of the PCOS subjects, confirming significant overexpression of CD163, TREM1, and TREM2. These findings contribute to a deeper understanding of the pathogenesis of PCOS.
    Journal
    |
    CD163 (CD163 Molecule)
    |
    CD163 overexpression • CD163 expression
    2ms
    Machine learning algorithms for predicting glioma patient prognosis based on CD163+FPR3+ macrophage signature. (PubMed, NPJ Precis Oncol)
    The risk score of this model consistently and effectively predicted overall survival, surpassing the accuracy of conventional clinical factors and 100 previously published signatures. Consequently, the CD163+FPR3+ macrophage-related score shows potential as a prognostic biomarker for glioma patients.
    Journal • Machine learning
    |
    CD163 (CD163 Molecule) • FPR3 (Formyl Peptide Receptor 3)
    |
    CD163 expression
    2ms
    Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer. (PubMed, BMC Cancer)
    Our study presents novel findings on mechanism of 2ME2 from the perspective of its effects on the polarization of the TAMs via the STAT3 signaling in breast cancer. Altogether, the data supports further clinical investigation of 2ME2 and its derivatives as therapeutic agents to modulate the tumor microenvironment and immune response in breast carcinoma.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • MRC1 (Mannose Receptor C-Type 1) • CCL18 (C-C Motif Chemokine Ligand 18)
    |
    CD20 expression • CD163 expression • MRC1 expression
    |
    Panzem (2-methoxyestradiol)
    6ms
    Direct assessment of leukocyte signalling and cytokine secretion reveals exercise intensity-dependent reductions in anti-inflammatory cytokine action. (PubMed, J Physiol)
    Changes in cytokine action were not explained by changes in cytokine receptor expression on circulating immune cells. Our findings provide new insights into the immunomodulatory effects of exercise in humans and highlight the importance of directly measuring cellular cytokine action when evaluating the anti-inflammatory effects of exercise.
    Journal
    |
    IL6 (Interleukin 6) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CD80 (CD80 Molecule)
    |
    CD163 expression
    6ms
    Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma. (PubMed, Med Oncol)
    A longer OS was reported in PD-L1 CPS negative patients (median OS NR vs 11.8 months; HR 0.20 p = 0.024). High infiltration of CD163+ macrophages, who typically present "anti-inflammatory" M2-like phenotype, could identify a subgroup of patients with poor survival after receiving first-line ICI.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD80 (CD80 Molecule)
    |
    PD-L1 negative • CD163 expression
    7ms
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    7ms
    Tumor and Peritoneum-Associated Macrophage Gene Signature as a Novel Molecular Biomarker in Gastric Cancer. (PubMed, Int J Mol Sci)
    Multivariate analyses confirmed M2TS was significantly and independently associated with survival. As an independent predictor of poor survival, M2TS may be prognostic in primary tumors and peritoneal fluid of GC patients.
    Journal • Gene Signature
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD36 (thrombospondin receptor) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • CCL23 (Chemokine (C-C motif) ligand 23) • GZMA (Granzyme A) • GZMH (Granzyme H) • MRC1 (Mannose Receptor C-Type 1) • PRF1 (Perforin 1) • CCL18 (C-C Motif Chemokine Ligand 18)
    |
    CD163 expression
    7ms
    Erdheim-Chester disease initially discovered at extraskeletal locations: a clinicopathological analysis of four cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    The fibrosis was more pronounced in the pleura and interlobular septa, and less pronounced in the alveolar septa. Immunohistochemical staining showed that all tumor cells expressed CD68, CD163 and F
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    BRAF V600E • BRAF V600 • CD163 expression
    7ms
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2028 --> May 2028 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    8ms
    CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov)
    P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
    |
    KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    8ms
    Exosome-transmitted podoplanin promotes tumor-associated macrophage-mediated immune tolerance in glioblastoma. (PubMed, CNS Neurosci Ther)
    This investigation underscores that EVsPDPN derived from glioblastoma cells contributes to M2 macrophage-mediated immunosuppression and is a potential prognostic marker and therapeutic target in glioblastoma.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CD68 (CD68 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • GFAP (Glial Fibrillary Acidic Protein)
    |
    MHC-II expression • CD163 expression
    8ms
    Single-cell RNA sequencing analysis of vestibular schwannoma reveals functionally distinct macrophage subsets. (PubMed, Br J Cancer)
    Macrophages form an important component of VS stroma. scRNAseq reveals three distinct subsets of macrophages in the VS tissue which may have differing roles in the pathogenesis of VS.
    Journal
    |
    AREG (Amphiregulin) • CD163 (CD163 Molecule) • SPP1 (Secreted Phosphoprotein 1) • PLCG2 (Phospholipase C Gamma 2) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • IL1B (Interleukin 1, beta) • ALOX15 (Arachidonate 15-Lipoxygenase) • PLAUR (Plasminogen Activator, Urokinase Receptor)
    |
    AREG expression • CD163 expression
    9ms
    ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms. (PubMed, Cancer Immunol Res)
    In a human tumor explant histoculture system, dual ILT2/ILT4 blockade increased CXCL9 secretion, downregulated CD163 expression, and increased the expression of M1 macrophage, IFN-γ, and cytolytic T cell gene signatures. Thus, we have revealed distinct contributions of ILT2 and ILT4 to myeloid cell biology and provide proof-of-concept data supporting the combined blockade of ILT2 and ILT4 to therapeutically induce optimal myeloid cell reprogramming in the tumor microenvironment.
    Journal
    |
    IFNG (Interferon, gamma) • CD163 (CD163 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD86 (CD86 Molecule)
    |
    CD163 expression
    9ms
    Gabapentin attenuates cardiac remodeling after myocardial infarction by inhibiting M1 macrophage polarization through the peroxisome proliferator-activated receptor-γ pathway. (PubMed, Eur J Pharmacol)
    Gabapentin attenuates cardiac remodeling by inhibiting inflammation via peroxisome proliferator-activated receptor-γ activation and preventing calcium overload.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    CD163 expression
    9ms
    Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment. (PubMed, Cancer Immunol Immunother)
    ZAG is suggested to be a novel immunoregulatory factor affecting the Mφ phenotype in breast cancer tissues.
    Journal
    |
    CD163 (CD163 Molecule) • MRC1 (Mannose Receptor C-Type 1) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    CD163 expression
    9ms
    Programmed Cell Death Ligand 1 Expression in CD163+ Tumor-associated Macrophages in Cancer Gland Rupture Microenvironment. (PubMed, Appl Immunohistochem Mol Morphol)
    High PD-L1 expression in CD163+ TAMs is associated with poor overall survival. Therefore, blocking PD-L1 in CD163+ TAMs can be used as a target for immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • PD-L1 overexpression • CD163 expression
    |
    PD-L1 IHC 22C3 pharmDx
    10ms
    The therapeutic effect of phellopterin on colitis-associated cancer and its effects on TLR4/NF-κB pathway and macrophage M2 polarization. (PubMed, Cell Mol Biol (Noisy-le-grand))
    The effect of phellopterin intervention on CAC was dose-dependent. In conclusion, phellopterin can improve the symptoms and inflammatory response of CAC and inhibit the occurrence of colon cancer (CC) by inhibiting M2 polarization of macrophages and activation of the TLR4/NF-κB pathway.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
    |
    CD163 expression
    10ms
    Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. (PubMed, BMC Pulm Med)
    In stage IA NSCLC, a low concentration of IFN-γ promotes the polarization of TAMs to the M2 phenotype in the TME model by upregulating the expression of IDO1, promoting the viability of cancer cells, inhibiting the viability of T cells and NK cells, and thus establishing an immune microenvironment conducive to tumor progression.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
    |
    BCL2 expression • CD20 expression • IDO1 expression • IFNG expression • BAX expression • CD163 expression • MRC1 expression
    10ms
    Niosomal hesperidin attenuates the M1/M2-macrophage polarization-based hepatotoxicity followed chlorpyrifos -induced toxicities in mice. (PubMed, Pestic Biochem Physiol)
    The ameliorative effects of Hesp and Nio + Hesp may be at least in part due to their antioxidant and anti-inflammatory properties. These findings showed that both M1- and M2-macrophages contributed to the development of hepatic lesions induced by CPF and provided information about macrophage activation, indicating the importance of analysis of macrophage phenotypes for hepatotoxicity based on M1/M2-polarization which can be downregulated by niosomal nesperidin.
    Preclinical • Journal
    |
    CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    CD163 overexpression • CD163 expression
    11ms
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Dec 2023 --> Feb 2024
    Trial initiation date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    11ms
    Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer. (PubMed, Medicine (Baltimore))
    Drug sensitivity analysis revealed that these hub genes could be potential therapeutic targets for the treatment of HGSOC. We constructed a risk model for the overall survival and explored the potential mechanism of monocyte in HGSOC.
    Journal
    |
    CD163 (CD163 Molecule)
    |
    CD163 expression
    11ms
    Correlation between F-FDG PET-derived parameters and quantitative pathological characteristics of soft tissue sarcoma. (PubMed, Quant Imaging Med Surg)
    F-FDG uptake was positively correlated with the quantitative pathological features of soft tissue tumors. SUV may be a meaningful method reflecting the level of M2 macrophage infiltration and may provide additional valuable information for preclinical evaluation of STS.
    Journal • FDG PET
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    CD163 expression
    11ms
    Comprehensive analysis of the role of netrin G1 (NTNG1) in hepatocellular carcinoma cells. (PubMed, Eur J Pharmacol)
    Additionally, an EMT inhibitor attenuated the expression levels of EMT-related markers and counteracted the effects of NTNG1 overexpression in liver cancer cells. This study is the first to identify NTNG1 as a potential therapeutic target in HCC, promoting tumor development and progression by regulating EMT.
    Journal
    |
    CD163 (CD163 Molecule) • CDH2 (Cadherin 2)
    |
    CD163 expression
    11ms
    Hypoxia-regulated exosomes mediate M2 macrophage polarization and promote metastasis in chondrosarcoma. (PubMed, Aging (Albany NY))
    Further analysis revealed that M2 macrophages polarized by exosomes expressed arginase-1 and feedback to chondrosarcoma cells to promote migration. These results suggest that chondrosarcoma cells secrete more exosomes in a hypoxic microenvironment, and these hypoxia-derived exosomes induce the polarization of macrophages into an M2 phenotype, ultimately promoting the metastatic behavior of chondrosarcoma cells.
    Journal
    |
    CD163 (CD163 Molecule) • ARG1 (Arginase 1) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
    |
    CD163 expression
    12ms
    Co-Occurrence of Clonally Related Follicular Lymphoma and Histiocytic Sarcoma (ASH 2023)
    By applying single cell genomics analyses to a combined FL/HS biopsy, our study aims to understand the evolutionary relationship of HS arising from FL, particularly whether the HS arose from an early dormant clone (branched evolution) or from a late, prevalent Fl clone (linear evolution). Evidence of the former would strengthen the view that common progenitor cells (CPCs) in FL are capable of differentiating into myeloid and lymphoid malignancies.
    IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CREBBP (CREB binding protein) • BIRC3 (Baculoviral IAP repeat containing 3) • CD163 (CD163 Molecule) • S100A8 (S100 Calcium Binding Protein A8) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • CD68 (CD68 Molecule) • STAT2 (Signal transducer and activator of transcription 2)
    |
    BCL2 expression • MYC expression • BCL2 rearrangement • CD163 expression • STAT2 expression
    12ms
    Unlocking the link between haptoglobin polymorphism and noninfectious human diseases: insights and implications. (PubMed, Crit Rev Clin Lab Sci)
    Therefore, the Hp1 allele may not necessarily confer advantages in all situations, and its effects may be context-dependent. This review highlights the current understanding of the role of Hp polymorphisms in cardiovascular disease, inflammatory bowel disease, cancer, transplantation, hemoglobinopathies, and polyuria.
    Review • Journal
    |
    CD163 (CD163 Molecule)
    |
    CD163 expression
    12ms
    Rosai-Dorfman Disease of the Breast: A Clinicoradiologic and Pathologic Study. (PubMed, Hum Pathol)
    Patients with RDD of the breast have an excellent prognosis after complete excision. KEW WORDS: Rosai-Dorfman disease; Breast Imaging-Reporting and Data System (BI-RADS); Immunohistochemistry; flow cytometry; kappa/lambda in situ hybridization.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CCND1 (Cyclin D1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    BRAF V600E • BRAF V600 • CCND1 expression • CD163 expression
    12ms
    Divergent Lineage Markers in Anaplastic Thyroid Carcinoma. (PubMed, Am J Surg Pathol)
    Twenty tested cases showed retained SMARCA4 expression. We conclude that ATCs express a number of divergent lineage markers that can cause diagnostic dilemmas, as they are also features of other tumors in the differential diagnosis of high-grade midline neck malignancies.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD163 (CD163 Molecule) • NKX2-1 (NK2 Homeobox 1) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
    |
    BRAF V600E • BRAF V600 • NRAS Q61 • NRAS Q61R • CD163 expression • TTF1 negative
    1year
    The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma. (PubMed, Cancers (Basel))
    The interactions between TAMs in situ and, particularly, CD206 macrophages are highly relevant to patient outcomes. High-resolution technology is important for identifying the roles of macrophage populations in tissue specimens and identifying potential therapeutic candidates in MPM.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
    |
    CD163 expression
    1year
    Prophylaxis of decidual CD68/CD163 macrophage disbalance in extracorporeal fertilized women. (PubMed, Heliyon)
    In women who became pregnant as a result of in vitro fertilization, at 28-30 weeks of pregnancy, changes specific for pro-inflammatory phenotype of decidual macrophages were observed. Complex administration of vitamin D3, micronized progesterone and l-arginine aspartate lead to restoration of anti-inflammatory phenotype of decidual macrophages.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CD68 (CD68 Molecule)
    |
    CD163 expression